Medical technology company AWAK Technologies (AWAK) has announced its move to new headquarters in Singapore to support growth over the next few years. The new 6,000 square foot office in Tuas houses 16 employees in research, regulatory and business development functions. AWAK will also have a fully-equipped chemistry lab, engineering lab and a clean room manufacturing facility to support the company’s research, development, manufacturing and commercial activities.
AWAK’s move to its new headquarters follows the appointment of AWAK’s new management team. Led by chief executive officer Suresh Venkataraya, the management team consists of:
- Mandar Gori, director of marketing and business development
- Daniel Tan, director of program management and operations
- Joel Preetham Fernandes, director of R&D and quality
- Carol Lim, head of finance and HR
The new management team has a combined global commercial experience of close to 50 years in medical devices covering R&D, finance, QA/RA, supply chain, manufacturing, sales, marketing, as well as FDA and CE approvals. It also underscores AWAK’s vision in bringing its patented sorbent technology that enables the development of ultra-portable peritoneal and haemodialysis machines to market globally.
AWAK has also recently formed a technical advisory committee, which will provide scientific guidance and advice on product development, comprised of senior advisors who are scientific experts in biochemistry, biopharmaceuticals and commercialisation of dialysis technologies. In addition, the medical advisory board includes experts such as Dr Gordon Ku (founder and chairman of Kidney Dialysis Foundation, Singapore) and Prof A. Vathsala (co-director of the National University Centre for Organ Transplantation at the National University Health System, Singapore).
Suresh Venkataraya, chief executive officer, AWAK, said: “We have made significant progress in recent years, including securing financing from Southeast Asia’s largest medtech company, Accuron MedTech, which will accelerate the research and development of our product. We expect to complete our first-in-human trial this quarter, a significant milestone for AWAK. I am excited about AWAK’s next phase of growth as we look to bring our revolutionary technology to markets globally and change the lives of end-stage renal disease patients worldwide.”
Photo / Provided